Yue Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yue Li has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Dalin Li
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
3 shared publications Hao Wang
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
3 shared publicationsKeru Ma
Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China
3 shared publicationsDongxu Yang
Department of Breast Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Harbin 150081, Heilongjiang, China
2 shared publicationsTianyu Chen
Department of Breast Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Harbin 150081, Heilongjiang, China
2 shared publicationsXue Gong
Department of Breast Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Harbin 150081, Heilongjiang, China
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Springer Nature in Journal of Nanobiotechnology
CD8⁺ T cell membrane-camouflaged cerium oxide nanozyme enables targeted delivery of a Gsk3β inhibitor to the immunological synapse, reconstructing immunological synapse homeostasis and alleviating limited immunotherapeutic responses in solid tumors by decoupling the β-Catenin-TIPE-PD-1 enhancer complex
- 3 September 2026
- Published by Springer Nature in Journal of Nanobiotechnology
Open AccessCD8⁺ T cell membrane-camouflaged cerium oxide nanozyme enables targeted delivery of a Gsk3β inhibitor to the immunological synapse, reconstructing immunological synapse homeostasis and alleviating limited immunotherapeutic responses in solid tumors by decoupling the β-Catenin-TIPE-PD-1 enhancer complex
- Top Cited Papers
- 11 February 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 392, 114716
Augmenting cuproptosis and anti-metastatic immunity in breast cancer by copper-based nanoplatform for synergistic immunotherapy via lactate metabolic reprogramming and hypoxia alleviation
- 11 February 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 392, 114716
Top Cited PapersAugmenting cuproptosis and anti-metastatic immunity in breast cancer by copper-based nanoplatform for synergistic immunotherapy via lactate metabolic reprogramming and hypoxia alleviation
- Open Access
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadw1553
Transition of cellular senescence to pyroptosis mediates recurrence of small cell lung cancer after chemotherapy
Chemotherapy-induced different cell fates play crucial roles in cancer treatment outcomes; however, the cross-talk between the cell fates during cancer recurrence remains unclear. Here, we found that the transition from cellular senescence to pyroptosis promoted small cell lung cancer (SCLC) recurrence after cisplatin and etoposide treatment. Parts of the senescent SCLC cells induced by chemotherapy showed positive cytoplasmic chromatin fragments (CCFs), and CCFs activated the ubiquitin-editing enzyme A20, which stabilized NLRP3 through its deubiquitinating activity, resulting in senescent cells undergoing pyroptosis. Subsequent inflammatory factors [such as interleukin-1 (IL-1)] released by pyroptosis promoted the acquisition of stem-like properties in CCF-negative senescent cells, ultimately promoting tumor recurrence. We also found that a combination of IL-1 receptor antagonist anakinra with chemotherapy delayed recurrence of SCLC, suggesting previously unidentified therapeutic strategies for SCLC.
- 11 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (28) , eadw1553
Open AccessTransition of cellular senescence to pyroptosis mediates recurrence of small cell lung cancer after chemotherapy
Chemotherapy-induced different cell fates play crucial roles in cancer treatment outcomes; however, the cross-talk between the cell fates during cancer recurrence remains unclear. Here, we found that the transition from cellular senescence to pyroptosis promoted small cell lung cancer (SCLC) recurrence after cisplatin and etoposide treatment. Parts of the senescent SCLC cells induced by chemotherapy showed positive cytoplasmic chromatin fragments (CCFs), and CCFs activated the ubiquitin-editing enzyme A20, which stabilized NLRP3 through its deubiquitinating activity, resulting in senescent cells undergoing pyroptosis. Subsequent inflammatory factors [such as interleukin-1 (IL-1)] released by pyroptosis promoted the acquisition of stem-like properties in CCF-negative senescent cells, ultimately promoting tumor recurrence. We also found that a combination of IL-1 receptor antagonist anakinra with chemotherapy delayed recurrence of SCLC, suggesting previously unidentified therapeutic strategies for SCLC.
- Open Access
- 19 May 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (5) , e70293
Mendelian Randomization Assessment of the Genetic Effects of Lipid‐Lowering Drugs on Digestive System Cancers
The relationship between lipid‐lowering drugs and the risk of digestive system cancers remains unclear. This study aims to assess the risk association between lipid‐lowering drugs and digestive system cancers through mendelian randomization (MR) analysis. We utilized genetic instruments to substitute for the exposure to lipid‐lowering drugs, including expression quantitative trait loci (eQTL) for HMGCR, PCSK9, and NPC1L1, as well as genetic variants associated with low‐density lipoprotein (LDL) from the Global Lipids Genetics Consortium's genome‐wide association study (GWAS) data for target genes. We used MR and SMR methods to assess the risk estimates of lipid‐lowering drug target genes on digestive system tumors. The MR analysis indicated a negative association between HMGCR‐mediated LDL and hepatocellular carcinoma (OR = 0.06, 95% CI: 0.00–0.81, p = 0.03), and a positive association between NPC1L1‐mediated LDL and gastric cancer risk (OR = 15.45, 95% CI: 5.96–40.56, p < 0.01). In the SMR analysis, it was observed that HMGCR expression decreased the risk of hepatocellular carcinoma (OR = 0.11, 95% CI: 0.02–0.68, p = 0.02), while NPC1L1 expression increased the risk of gastric cancer (OR = 1.33, 95% CI: 1.08–1.64, p < 0.01). Our study results suggested a potential risk association between HMGCR inhibitors and NPC1L1 with hepatocellular carcinoma and gastric cancer.
- 19 May 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (5) , e70293
Open AccessMendelian Randomization Assessment of the Genetic Effects of Lipid‐Lowering Drugs on Digestive System Cancers
The relationship between lipid‐lowering drugs and the risk of digestive system cancers remains unclear. This study aims to assess the risk association between lipid‐lowering drugs and digestive system cancers through mendelian randomization (MR) analysis. We utilized genetic instruments to substitute for the exposure to lipid‐lowering drugs, including expression quantitative trait loci (eQTL) for HMGCR, PCSK9, and NPC1L1, as well as genetic variants associated with low‐density lipoprotein (LDL) from the Global Lipids Genetics Consortium's genome‐wide association study (GWAS) data for target genes. We used MR and SMR methods to assess the risk estimates of lipid‐lowering drug target genes on digestive system tumors. The MR analysis indicated a negative association between HMGCR‐mediated LDL and hepatocellular carcinoma (OR = 0.06, 95% CI: 0.00–0.81, p = 0.03), and a positive association between NPC1L1‐mediated LDL and gastric cancer risk (OR = 15.45, 95% CI: 5.96–40.56, p < 0.01). In the SMR analysis, it was observed that HMGCR expression decreased the risk of hepatocellular carcinoma (OR = 0.11, 95% CI: 0.02–0.68, p = 0.02), while NPC1L1 expression increased the risk of gastric cancer (OR = 1.33, 95% CI: 1.08–1.64, p < 0.01). Our study results suggested a potential risk association between HMGCR inhibitors and NPC1L1 with hepatocellular carcinoma and gastric cancer.
- Open Access
- 17 June 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1396606
Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report
Background: Niraparib, a poly ADP-ribose polymerase inhibitors (PARPi), has been widely applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Nevertheless, as of the present moment, there are limited instances demonstrating favorable outcomes stemming from niraparib therapy in patients with clear cell renal cell carcinoma (ccRCC).Case presentation: Here, we report a case of a 50-year-old patient with ccRCC who subsequently developed distant metastasis. The patient received monotherapy with pazopanib and combination therapy with axitinib and tislelizumab, demonstrating limited efficacy. Liquid biopsy revealed missense mutations in the CDK12 and RAD51C of the homologous recombination repair (HRR) pathway, suggesting potential sensitivity to PARPi. Following niraparib treatment, the patient’s condition improved, with no significant side effects.Conclusion: In summary, patients with ccRCC harboring HRR pathway gene mutation may potentially benefit from niraparib. This will present more options for ccRCC patients with limited response to conventional treatments.
- 17 June 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1396606
Open AccessNiraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report
Background: Niraparib, a poly ADP-ribose polymerase inhibitors (PARPi), has been widely applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Nevertheless, as of the present moment, there are limited instances demonstrating favorable outcomes stemming from niraparib therapy in patients with clear cell renal cell carcinoma (ccRCC).Case presentation: Here, we report a case of a 50-year-old patient with ccRCC who subsequently developed distant metastasis. The patient received monotherapy with pazopanib and combination therapy with axitinib and tislelizumab, demonstrating limited efficacy. Liquid biopsy revealed missense mutations in the CDK12 and RAD51C of the homologous recombination repair (HRR) pathway, suggesting potential sensitivity to PARPi. Following niraparib treatment, the patient’s condition improved, with no significant side effects.Conclusion: In summary, patients with ccRCC harboring HRR pathway gene mutation may potentially benefit from niraparib. This will present more options for ccRCC patients with limited response to conventional treatments.
- Open Access
Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study
Background: In contrast to Caucasian melanoma, which has been extensively studied, there are few studies on melanoma in Asian populations. Sporadic studies reported that only 40% of Asian melanoma patients could be druggable, which was much lower than that in Caucasians. More studies are required to refine this conclusion. Methods: Chinese melanoma patients (n = 469) were sequentially sequenced by DNA-NGS and RNA-NGS. The genomic alterations were determined, and potentially actionable targets were investigated. Results: Patients with potential druggable targets were identified in 75% of Chinese melanoma patients by DNA-NGS based on OncoKB, which was much higher than in a previous Asian study. NRG1 fusions were first identified in melanoma. In addition, up to 11.7% (7/60) of patients in the undruggable group could be recognized as actionable by including RNA-NGS analysis. By comparing the fusion detection rate between DNA-NGS and RNA-NGS, all available samples after DNA-NGS detection were further verified by RNA-NGS. The use of RNA-NGS enhanced the proportion of druggable fusions from 2.56% to 17.27%. In total, the use of RNA-NGS increased the druggable proportion from 75% to 78%. Conclusions: In this study, we systemically analyzed the actionable landscape of melanoma in the largest Asian cohort. In addition, we first demonstrated how DNA and RNA sequential sequencing is essential in bringing clinical benefits to more patients with melanoma.
Open AccessGenomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study
Background: In contrast to Caucasian melanoma, which has been extensively studied, there are few studies on melanoma in Asian populations. Sporadic studies reported that only 40% of Asian melanoma patients could be druggable, which was much lower than that in Caucasians. More studies are required to refine this conclusion. Methods: Chinese melanoma patients (n = 469) were sequentially sequenced by DNA-NGS and RNA-NGS. The genomic alterations were determined, and potentially actionable targets were investigated. Results: Patients with potential druggable targets were identified in 75% of Chinese melanoma patients by DNA-NGS based on OncoKB, which was much higher than in a previous Asian study. NRG1 fusions were first identified in melanoma. In addition, up to 11.7% (7/60) of patients in the undruggable group could be recognized as actionable by including RNA-NGS analysis. By comparing the fusion detection rate between DNA-NGS and RNA-NGS, all available samples after DNA-NGS detection were further verified by RNA-NGS. The use of RNA-NGS enhanced the proportion of druggable fusions from 2.56% to 17.27%. In total, the use of RNA-NGS increased the druggable proportion from 75% to 78%. Conclusions: In this study, we systemically analyzed the actionable landscape of melanoma in the largest Asian cohort. In addition, we first demonstrated how DNA and RNA sequential sequencing is essential in bringing clinical benefits to more patients with melanoma.
- Open Access
- 11 April 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-10
Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer
Programmed cell death 1 ligand 1 (PD-L1) has been approved as predictive biomarker for non-small-cell lung cancer (NSCLC) patients treated with PD-(L)1 blockade therapy. The clinical/genomic features associated with PD-L1 are not well studied. Genomic profiling of tumor biopsies from 883 Chinese NSCLC patients was performed by targeted next-generation sequencing. Immunohistochemical analysis was conducted to evaluate PD-L1 expression levels using antibodies Dako 22C3 and 28-8, respectively. Our study showed distinct correlation between PD-L1 expression and clinical/genomic characteristics when using different PD-L1 antibodies and in different histological subtypes including adenocarcinoma (ADC) and squamous cell carcinoma (SCC), respectively. PD-L1 high expression (22C3) was associated with male and lymph node metastasis only in ADC patients. Furthermore, mutations of TP53 and KRAS, KIF5B-RET fusion, copy number gains of PD-L1 and PD-L2, and arm-level amplifications of chr.12p were significantly associated with PD-L1 positive status in ADC patients. For SCC patients, the gain of EGFR and MDM2 and loss of PTPRD were negatively associated with PD-L1 expression. We also compared our results with other studies and found conflicting results presumably because of the multiplicity of antibody clones and platforms, the difference of cutoffs for assigning PD-L1 expression levels, and the variation in study populations. Our study can help to understand the utility and validity of PD-L1 as biomarker of response to immune checkpoint inhibitors.
- 11 April 2022
- Published by Wiley in Journal of Oncology
- Vol. 2022, 1-10
Open AccessCorrelation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer
Programmed cell death 1 ligand 1 (PD-L1) has been approved as predictive biomarker for non-small-cell lung cancer (NSCLC) patients treated with PD-(L)1 blockade therapy. The clinical/genomic features associated with PD-L1 are not well studied. Genomic profiling of tumor biopsies from 883 Chinese NSCLC patients was performed by targeted next-generation sequencing. Immunohistochemical analysis was conducted to evaluate PD-L1 expression levels using antibodies Dako 22C3 and 28-8, respectively. Our study showed distinct correlation between PD-L1 expression and clinical/genomic characteristics when using different PD-L1 antibodies and in different histological subtypes including adenocarcinoma (ADC) and squamous cell carcinoma (SCC), respectively. PD-L1 high expression (22C3) was associated with male and lymph node metastasis only in ADC patients. Furthermore, mutations of TP53 and KRAS, KIF5B-RET fusion, copy number gains of PD-L1 and PD-L2, and arm-level amplifications of chr.12p were significantly associated with PD-L1 positive status in ADC patients. For SCC patients, the gain of EGFR and MDM2 and loss of PTPRD were negatively associated with PD-L1 expression. We also compared our results with other studies and found conflicting results presumably because of the multiplicity of antibody clones and platforms, the difference of cutoffs for assigning PD-L1 expression levels, and the variation in study populations. Our study can help to understand the utility and validity of PD-L1 as biomarker of response to immune checkpoint inhibitors.
- Open Access
- 1 September 2020
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 21, 804-813
lncRNA LCPAT1 Upregulation Promotes Breast Cancer Progression via Enhancing MFAP2 Transcription
- 1 September 2020
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 21, 804-813
Open AccesslncRNA LCPAT1 Upregulation Promotes Breast Cancer Progression via Enhancing MFAP2 Transcription
- Open Access
- 14 August 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (51) , 88622-88629
Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility
Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility
- 14 August 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (51) , 88622-88629
Open AccessToll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility
Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility